There can be value in speculation, just don't take it as fact. It can help narrowing down which hypothetical compounds may be more interesting than others. You use SAR based on known substitutions, for example most N-substituted PEA psychedelics other than PEA empathogens which follow different SAR, do not appear to be that interesting if you read PiHKAL.
So, it's still worth noting that putting even one methyl on the amine lowers the potency of a PEA about ten-fold... what makes up for that is if you substitute not a methyl but something like certain kinds of N-benzyl or NDEPA which overlay with a pharmacophore that extends beyond tryptamines and phenethylamines that some lysergamides like LSD also relate to.
Nobody asked about a certain calculation of the effects, but you can still try to extrapolate what is known. Pioneering is a combination of on the one hand trying variations that may not quite follow all SAR predictions because as you say: we don't really know and you might find novel compounds that way... but on the other hand, it's reasonable to speculate in order to filter a little bit in what is expected to fit in current models at least somewhat... because you can't randomly try everything, it's costly so ridiculous. Also speculation helps with motivating and dreaming about what has not yet been done.
So not saying this couldn't possibly have action, it very well could...
If THIQs like that are active by virtue of that particular moiety, it's very curious that it is hanging off a 2C-B structure which is not likely to have much to do with it and may very well be posing limitations on the actual THIQ compounds. It would sort of be a hybrid of drugs which is generally not a good idea, certainly not to start discoveries with. If that is not the case and it is actually the complete molecule that is active as a psychedelic you would expect it to follow some of the rules you also see the N-benzyl and NDEPAs and lysergamides following because those demonstrate at which positions certain groups are tolerated, not tolerated or actually critical to the activity.
In this case it actually looks alright because it is basically a cyclized and constrained N-benzyl group so it could be NBOMe-like. Guess I hadn't really thought about it like that. It would probably be improved by a methoxy or fluoro on the THIQ aromatic ring just like NBOMe's > basic N-benzyls like N-benzyl-2C-B which has been tested.
It's really extreme to suggest that SAR speculations are completely pointless in any stage. I must admit that it would be quite interesting to see whether the NBOMe likeness is good enough for it to be quite active or if the tertiary amine just isn't tolerated whatsoever.
I just think that the latter is the case because of Shulgin writing things like this:
N,N-Dimethylmescaline has been given the trivial name of Trichocerine as it has been found as a natural product in several cacti of the Trichocereus Genus but, interestingly, never in any Peyote variant. It also has proven inactive in man in dosages in excess of 500 milligrams, administered parenterally. This observation, the absence of activity of a simple tertiary amine, has been exploited in the development of several iodinated radiopharmaceuticals that are mentioned elsewhere in this book.
Tried checking the Shulgin Index but I'm not really seeing interesting entries for tertiary amines at a quick glance.
If you're not presumptious about what we don't know, I'm not presumptious about what we do know - deal?